|
| 37992310 | A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer. | Clin Cancer Res | 2024 |
| 36350312 | A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. | Clin Cancer Res | 2023 |
| 37596538 | Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer. | BMC Cancer | 2023 |
| 34724226 | Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. | Int J Cancer | 2022 |
| 34255512 | Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors. | J Med Chem | 2021 |
| 34274316 | GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice. | J Biol Chem | 2021 |
| 32307821 | Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma. | Pediatr Blood Cancer | 2020 |
| 32328561 | Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. | JNCI Cancer Spectr | 2019 |
| 29674704 | MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers. | Oncogenesis | 2018 |
| 24009722 | BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. | PLoS One | 2013 |
| 24293458 | Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. | Oncotarget | 2013 |
| 20610535 | Research Resource: The androgen receptor modulates expression of genes with critical roles in muscle development and function. | Mol Endocrinol | 2010 |
| 18206973 | The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. | Mol Cell | 2008 |
| 17643376 | H2B ubiquitylation acts as a barrier to Ctk1 nucleosomal recruitment prior to removal by Ubp8 within a SAGA-related complex. | Mol Cell | 2007 |
| 16531232 | Structure and dimerization of the kinase domain from yeast Snf1, a member of the Snf1/AMPK protein family. | Structure | 2006 |
| 15721261 | Maintenance of low histone ubiquitylation by Ubp10 correlates with telomere-proximal Sir2 association and gene silencing. | Mol Cell | 2005 |
| 15657441 | H2B ubiquitin protease Ubp8 and Sgf11 constitute a discrete functional module within the Saccharomyces cerevisiae SAGA complex. | Mol Cell Biol | 2005 |
| 15171247 | H2B ubiquitylation and de-ubiquitylation in gene activation. | Novartis Found Symp | 2004 |
| 14563679 | Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. | Genes Dev | 2003 |
| 11756452 | A novel WD repeat protein component of the methylosome binds Sm proteins. | J Biol Chem | 2002 |
| 11389857 | SMN, the product of the spinal muscular atrophy gene, binds preferentially to dimethylarginine-containing protein targets. | Mol Cell | 2001 |
| 11713266 | The methylosome, a 20S complex containing JBP1 and pICln, produces dimethylarginine-modified Sm proteins. | Mol Cell Biol | 2001 |